Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12560358 | 0.74 | DRD1 (0.49) | DRD1MKNK1ALDH1A1LMNAKMT2A | |
| SCHEMBL10435709 | 0.74 | DRD1 (0.36) | DRD1ALDH1A1LMNAKMT2AKCNA3 | |
| SCHEMBL12559880 | 0.74 | DRD1 (0.36) | DRD1ALDH1A1LMNAKMT2AKCNA3 | |
| SCHEMBL29807239 | 0.71 | AXL (0.41) | AXLSMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL17329007 | 0.71 | AXL (0.41) | AXLSMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL4439756 | 0.70 | KDM4E (0.34) | ALDH1A1LMNAKMT2AKCNA3KDM4E | |
| SCHEMBL30324572 | 0.70 | KDM4E (0.34) | ALDH1A1LMNAKMT2AKCNA3KDM4E | |
| SCHEMBL12395097 | 0.69 | DRD1 (0.37) | DRD1ALDH1A1LMNAKMT2APRKDC | |
| SCHEMBL12395126 | 0.69 | DRD1 (0.37) | DRD1ALDH1A1LMNAKMT2AKDM4E | |
| SCHEMBL24795857 | 0.68 | ADORA2A (0.52) | DRD1ALDH1A1KMT2AGPR55KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146226-A | Pyrrolo [2,3-d ] pyrimidine compound with nitrogen-containing heterocyclic structure, and preparation method and application thereof | 贵州大学 | 2024-06-07 | — | — | CN | claimed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4532495-A1 | CD73 INHIBITOR COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025067384-A1 | AMINO ACID INTEGRIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都微芯药业有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119585273-A | CD73 inhibitor compounds | 阿道尔克斯治疗有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PDE4A 2219/4885PDE4B 2986/4885PDE4C 2581/4885 |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | PDE4A 1156/4885PDE4B 1241/4885PDE4C 921/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | PDE4A 3466/4885PDE4B 3557/4885PDE4C 3510/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | PDE4A 87/4885PDE4B 86/4885PDE4C 85/4885 |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | PDE4A 4623/4885PDE4B 4749/4885PDE4C 4733/4885 |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | PDE4A 197/4885PDE4B 277/4885PDE4C 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.